BioSpace News Archive

Amgen will present at the Evercore ISI HealthCONx Conference at 9:10 a.m. EST on Wednesday, Nov. 29, 2023.

Atara Biotherapeutics, Inc. announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 10:50 a.m. EST.

Enanta Pharmaceuticals, Inc. today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Evercore ISI HealthCONx Conference on November 29, 2023 at 7:55 a.m. ET in Miami, FL.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) and AnHeart Therapeutics (“AnHeart”) announce that the New Drug Application (NDA) for taletrectinib, has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have been previously treated with ROS1 TKIs.

Bayer continues to advance its comprehensive Radiology portfolio with progress in the development pipeline for an investigational contrast agent as well as new innovations in the area of Artificial Intelligence.

AbelZeta Pharma, Inc. announced today that two abstracts relating to its immuno-oncology drug development have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Diego, California, and online from December 9 to 12, 2023.

Northwest Biotherapeutics provided an update today about the final preparations for the Marketing Authorization Application (MAA) that will be submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA) in the U.K. for commercial approval of the Company’s DCVax®-L treatment for glioblastoma.

The U.S. molecular diagnostics market size was exhibited at USD 6.1 billion in 2022 and it is expected to hit around USD 9.78 billion by 2032, growing at a CAGR of 4.83% during the forecast period from 2023 to 2032.

The U.S. In Vitro Diagnostics Market in terms of revenue was estimated to be worth USD 58 billion in 2022 and is poised to reach USD 93.58 billion by 2032, growing at a CAGR of 4.90% from 2023 to 2032 according to a new report by Nova One Advisor.

4DMedical, the leading producer of advanced lung function imaging software has received FDA clearance for its CT-based ventilation product (CT LVAS™).